<DOC>
	<DOCNO>NCT02348099</DOCNO>
	<brief_summary>This pilot study enroll 100 people assess incidence lipohypertrophy detect ultrasound impact glycemic variability .</brief_summary>
	<brief_title>Ultrasound Detection Characterization Subclinical Hypertrophy Diabetes</brief_title>
	<detailed_description>Lipohypertrophy well document phenomenon patient diabetes hypertrophy differentiation adipocytes occurs dermal reticular layer sit subcutaneous insulin injection . Currently , lipohypertrophy assess palpate insulin injection site . The detection early , non palpable ( subclinical ) lipohypertrophy remain difficult clinical setting . Recent study identify distinct ultrasonographic feature hyperechogenicity area adipose tissue consistent clinical evidence lipohypertrophy insulin injection site , detect change int thickness subcutaneous tissue clinically evident population patient type 1 diabetes . Lipohypertrophy adversely affect glycemic control . Injecting lipohypertrophic area lead poor absorption need increase dos insulin . In study study participant undergo 2 assessment lipohypertrophy baseline , 3 , 6 12 month . A Diabetes Nurse ass lipohypertrophy palpation accord FIT Protocol . A second diabetes nurse present palpation ass insulin injection sit lipohypertrophy ultrasound use linear probe .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>19 year age old Type 1 Type 2 diabetes Using insulin manage diabetes least 2 year Using insulin pump , insulin secretagogues , GlucagonLike Peptide1 ( GLP1 ) agonists manage diabetes Use immunosuppressant agent Women pregnant</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Lipohypertrophy</keyword>
	<keyword>Ultrasound</keyword>
</DOC>